AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-95
Results: 1-25/95
HIGH-DOSE CHEMOTHERAPY - HOW RESISTANT IS BREAST-CANCER
Authors: PUSZTAI L HORTOBAGYI GN
Citation: L. Pusztai et Gn. Hortobagyi, HIGH-DOSE CHEMOTHERAPY - HOW RESISTANT IS BREAST-CANCER, DRUG RESISTANCE UPDATES, 1(1), 1998, pp. 62-72
PATHOLOGICAL TUMOR RESPONSE IN THE BREAST FOLLOWING NEOADJUVANT CHEMOTHERAPY PREDICTS AXILLARY LYMPH-NODE STATUS
Authors: KUERER HM NEWMAN LA BUZDAR AU DHINGRA K HUNT KK BUCHHOLZ TA BINKLEY SM STROM EA AMES FC ROSS MI FEIG BW MCNEESE MD HORTOBAGYI GN SINGLETARY SE
Citation: Hm. Kuerer et al., PATHOLOGICAL TUMOR RESPONSE IN THE BREAST FOLLOWING NEOADJUVANT CHEMOTHERAPY PREDICTS AXILLARY LYMPH-NODE STATUS, The cancer journal from Scientific American, 4(4), 1998, pp. 230-236
A PHASE-I MULTICENTER STUDY OF E1A GENE-THERAPY FOR PATIENTS WITH METASTATIC BREAST-CANCER AND EPITHELIAL OVARIAN-CANCER THAT OVEREXPRESSESHER-2 NEU OR EPITHELIAL OVARIAN-CANCER/
Authors: HORTOBAGYI GN HUNG MC
Citation: Gn. Hortobagyi et Mc. Hung, A PHASE-I MULTICENTER STUDY OF E1A GENE-THERAPY FOR PATIENTS WITH METASTATIC BREAST-CANCER AND EPITHELIAL OVARIAN-CANCER THAT OVEREXPRESSESHER-2 NEU OR EPITHELIAL OVARIAN-CANCER/, Human gene therapy, 9(12), 1998, pp. 1775-1798
PHASE-II STUDY OF ADOZELESIN IN UNTREATED METASTATIC BREAST-CANCER
Authors: CRISTOFANILLI M BRYAN WJ MILLER LL CHANG AYC GRADISHAR WJ KUFE DW HORTOBAGYI GN
Citation: M. Cristofanilli et al., PHASE-II STUDY OF ADOZELESIN IN UNTREATED METASTATIC BREAST-CANCER, Anti-cancer drugs, 9(9), 1998, pp. 779-782
TYROSINE KINASE INHIBITORS, EMODIN AND ITS DERIVATIVE REPRESS HER-2 NEU-INDUCED CELLULAR-TRANSFORMATION AND METASTASIS-ASSOCIATED PROPERTIES/
Authors: ZHANG LS LAU YK XI L HONG RL KIM DS CHEN CF HORTOBAGYI GN CHANG CJ HUNG MC
Citation: Ls. Zhang et al., TYROSINE KINASE INHIBITORS, EMODIN AND ITS DERIVATIVE REPRESS HER-2 NEU-INDUCED CELLULAR-TRANSFORMATION AND METASTASIS-ASSOCIATED PROPERTIES/, Oncogene, 16(22), 1998, pp. 2855-2863
OVEREXPRESSION OF BOTH P185(C-ERBB2) AND P170(MDR-1) RENDERS BREAST-CANCER CELLS HIGHLY RESISTANT TO TAXOL
Authors: YU DH LIU BL JING T SUN DT PRICE JE SINGLETARY SE IBRAHIM N HORTOBAGYI GN HUNG MC
Citation: Dh. Yu et al., OVEREXPRESSION OF BOTH P185(C-ERBB2) AND P170(MDR-1) RENDERS BREAST-CANCER CELLS HIGHLY RESISTANT TO TAXOL, Oncogene, 16(16), 1998, pp. 2087-2094
CLINICAL COURSE OF BREAST-CANCER PATIENTS WITH METASTASES CONFINED TOTHE LUNGS TREATED WITH CHEMOTHERAPY
Authors: DIAZCANTON EA VALERO V RAHMAN Z RODRIGUEZMONGE E FRYE D SMITH T BUZDAR AU HORTOBAGYI GN
Citation: Ea. Diazcanton et al., CLINICAL COURSE OF BREAST-CANCER PATIENTS WITH METASTASES CONFINED TOTHE LUNGS TREATED WITH CHEMOTHERAPY, Annals of oncology, 9(4), 1998, pp. 413-418
A PHASE-II OPEN-LABEL STUDY TO EVALUATE A 28-DAY ORAL REGIMEN OF 5-FLUOROURACIL (5-FU) PLUS ENILURACIL FOR THE TREATMENT OF PATIENTS WITH TAXANE AND ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS
Authors: RIVERA E CHEVLEN E ECKARDT J KENNEDY MJ SAWHNEY R SUTTON L FRYE D HEDRICK J MCGUIRT C LEVIN J HOHNEKER J WHITE R HORTOBAGYI GN
Citation: E. Rivera et al., A PHASE-II OPEN-LABEL STUDY TO EVALUATE A 28-DAY ORAL REGIMEN OF 5-FLUOROURACIL (5-FU) PLUS ENILURACIL FOR THE TREATMENT OF PATIENTS WITH TAXANE AND ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS, Annals of oncology, 9, 1998, pp. 70-70
TAMOXIFEN AS PRIMARY THERAPY IN COMBINED-MODALITY TREATMENT OF ELDERLY PATIENTS WITH LOCALLY ADVANCED BREAST-CANCER
Authors: VALERO V HOFF P SINGLETARY ES BUZDAR AU BOOSER DJ ASMAR L MCNEESE M HORTOBAGYI GN
Citation: V. Valero et al., TAMOXIFEN AS PRIMARY THERAPY IN COMBINED-MODALITY TREATMENT OF ELDERLY PATIENTS WITH LOCALLY ADVANCED BREAST-CANCER, Annals of oncology, 9, 1998, pp. 78-78
ADJUVANT ANTHRACYCLINE-CONTAINING THERAPY IN WOMEN GREATER-THAN-OR-EQUAL-TO-65 YEARS WITH BREAST-CANCER - THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE
Authors: VALERO V BUZDAR AU ASMAR L THERIAULT RL BOOSER DJ MCNEESE M SINGLETARY SE HORTOBAGYI GN
Citation: V. Valero et al., ADJUVANT ANTHRACYCLINE-CONTAINING THERAPY IN WOMEN GREATER-THAN-OR-EQUAL-TO-65 YEARS WITH BREAST-CANCER - THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE, Annals of oncology, 9, 1998, pp. 144-144
PACLITAXEL AS A SINGLE-AGENT THERAPY IN WOMEN GREATER-THAN-OR-EQUAL-TO-65 YEARS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER - THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE
Authors: VALERO V HOLMES FA FRYE D THERIAULT RL ESPARZAGUERRA L HORTOBAGYI GN
Citation: V. Valero et al., PACLITAXEL AS A SINGLE-AGENT THERAPY IN WOMEN GREATER-THAN-OR-EQUAL-TO-65 YEARS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER - THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE, Annals of oncology, 9, 1998, pp. 145-145
ANASTROZOLE (ARIMIDEX(R)), A NEW AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - MECHANISM OF ACTION AND ROLE IN MANAGEMENT
Authors: HORTOBAGYI GN BUZDAR AU
Citation: Gn. Hortobagyi et Au. Buzdar, ANASTROZOLE (ARIMIDEX(R)), A NEW AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - MECHANISM OF ACTION AND ROLE IN MANAGEMENT, Cancer investigation, 16(6), 1998, pp. 385-390
PILOT-STUDY OF BONE-MINERAL DENSITY IN BREAST-CANCER PATIENTS TREATEDWITH ADJUVANT CHEMOTHERAPY
Authors: HEADLEY JA THERIAULT RL LEBLANC AD VASSILOPOULOUSELLIN R HORTOBAGYI GN
Citation: Ja. Headley et al., PILOT-STUDY OF BONE-MINERAL DENSITY IN BREAST-CANCER PATIENTS TREATEDWITH ADJUVANT CHEMOTHERAPY, Cancer investigation, 16(1), 1998, pp. 6-11
LONG-TERM PREVENTION OF SKELETAL COMPLICATIONS OF METASTATIC BREAST-CANCER WITH PAMIDRONATE
Authors: HORTOBAGYI GN THERIAULT RL LIPTON A PORTER L BLAYNEY D SINOFF C WHEELER H SIMEONE JF SEAMAN JJ KNIGHT RD HEFFERNAN M MELLARS K REITSMA DJ
Citation: Gn. Hortobagyi et al., LONG-TERM PREVENTION OF SKELETAL COMPLICATIONS OF METASTATIC BREAST-CANCER WITH PAMIDRONATE, Journal of clinical oncology, 16(6), 1998, pp. 2038-2044
DIFFERENCES IN TOXICITY FINDINGS FOR ANTIESTROGENS - REPLY
Authors: BUZDAR AU HORTOBAGYI GN
Citation: Au. Buzdar et Gn. Hortobagyi, DIFFERENCES IN TOXICITY FINDINGS FOR ANTIESTROGENS - REPLY, Journal of clinical oncology, 16(5), 1998, pp. 2000-2000
ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR POOR-RISK PATIENTS WITH METASTATIC BREAST-CANCER
Authors: UENO NT RONDON G MIRZA NQ GEISLER DK ANDERLINI P GIRALT SA ANDERSSON BS CLAXTON DF GAJEWSKI JL KHOURI IF KORBLING M MEHRA RC PRZEPIORKA D RAHMAN Z SAMUELS BI VANBESIEN K HORTOBAGYI GN CHAMPLIN RE
Citation: Nt. Ueno et al., ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR POOR-RISK PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 16(3), 1998, pp. 986-993
PATIENT SELECTION IN HIGH-DOSE TRIALS OF BREAST-CANCER - REPLY
Authors: RAHMAN Z BUZDAR A HORTOBAGYI GN
Citation: Z. Rahman et al., PATIENT SELECTION IN HIGH-DOSE TRIALS OF BREAST-CANCER - REPLY, Journal of clinical oncology, 16(3), 1998, pp. 1239-1239
A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER
Authors: VALERO V JONES SE VONHOFF DD BOOSER DJ MENNEL RG RAVDIN PM HOLMES FA RAHMAN Z SCHOTTSTAEDT MW ERBAN JK ESPARZAGUERRA L EARHART RH HORTOBAGYI GN BURRIS HA
Citation: V. Valero et al., A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER, Journal of clinical oncology, 16(10), 1998, pp. 3362-3368
TAMOXIFEN AND TOREMIFENE IN BREAST-CANCER - COMPARISON OF SAFETY AND EFFICACY
Authors: BUZDAR AU HORTOBAGYI GN
Citation: Au. Buzdar et Gn. Hortobagyi, TAMOXIFEN AND TOREMIFENE IN BREAST-CANCER - COMPARISON OF SAFETY AND EFFICACY, Journal of clinical oncology, 16(1), 1998, pp. 348-353
REGISTRY RESULTS AND HIGH-DOSE THERAPY
Authors: RAVDIN PM CALLANDER NS HORTOBAGYI GN
Citation: Pm. Ravdin et al., REGISTRY RESULTS AND HIGH-DOSE THERAPY, Journal of clinical oncology, 16(1), 1998, pp. 387-388
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT IN PATIENTS WITH BREAST-CANCER
Authors: RAHMAN ZU HORTOBAGYI GN BUZDAR AU CHAMPLIN R
Citation: Zu. Rahman et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT IN PATIENTS WITH BREAST-CANCER, Cancer treatment reviews, 24(4), 1998, pp. 249-263
DAILY ORAL ETOPOSIDE IN PATIENTS WITH HEAVILY PRETREATED METASTATIC BREAST-CANCER
Authors: PUSZTAI L WALTERS RS VALERO V THERIAULT RL HORTOBAGYI GN
Citation: L. Pusztai et al., DAILY ORAL ETOPOSIDE IN PATIENTS WITH HEAVILY PRETREATED METASTATIC BREAST-CANCER, American journal of clinical oncology, 21(5), 1998, pp. 442-446
PHASE-II STUDY OF IFOSFAMIDE AND MESNA IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: WALTERS RS HOLMES FA VALERO V ESPARZAGUERRA L HORTOBAGYI GN
Citation: Rs. Walters et al., PHASE-II STUDY OF IFOSFAMIDE AND MESNA IN PATIENTS WITH METASTATIC BREAST-CANCER, American journal of clinical oncology, 21(4), 1998, pp. 413-415
EXPRESSION OF LEUKEMIA INHIBITORY FACTOR AND ITS RECEPTOR IN BREAST-CANCER - A POTENTIAL AUTOCRINE AND PARACRINE GROWTH-REGULATORY MECHANISM
Authors: DHINGRA K SAHIN A EMAMI K HORTOBAGYI GN ESTROV Z
Citation: K. Dhingra et al., EXPRESSION OF LEUKEMIA INHIBITORY FACTOR AND ITS RECEPTOR IN BREAST-CANCER - A POTENTIAL AUTOCRINE AND PARACRINE GROWTH-REGULATORY MECHANISM, Breast cancer research and treatment, 48(2), 1998, pp. 165-174
HIGH-DOSE CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - REPLY
Authors: PUSZTAI L HORTOBAGYI GN
Citation: L. Pusztai et Gn. Hortobagyi, HIGH-DOSE CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - REPLY, Lancet, 352(9139), 1998, pp. 1552-1552
Risultati: 1-25 | 26-50 | 51-75 | 76-95